Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study

被引：0

作者：

Teppei Okamoto

Daisuke Noro

Shingo Hatakeyama

Shintaro Narita

Koji Mitsuzuka

Toshihiko Sakurai

Sadafumi Kawamura

Senji Hoshi

Jiro Shimoda

Toshikazu Tanaka

Toshiaki Kawaguchi

Shigeto Ishidoya

Akihiro Ito

Norihiko Tsuchiya

Tomonori Habuchi

Chikara Ohyama

机构：

[1] Hirosaki University Graduate School of Medicine,Department of Urology, Department of Advanced Blood Purification Therapy

[2] Akita University School of Medicine,Department of Urology

[3] Tohoku University School of Medicine,Department of Urology

[4] Yamagata University School of Medicine,Department of Urology

[5] Miyagi Cancer Center,Department of Urology

[6] Yamagata Prefectural Central Hospital,Department of Urology

[7] Iwate Prefectural Isawa Hospital,Department of Urology

[8] Aomori Prefectural Central Hospital,Department of Urology

[9] Sendai City Hospital,Department of Urology

来源：

BMC Cancer | / 21卷

关键词：

Prostate cancer; Hormone-sensitive; Abiraterone acetate; Upfront therapy; Prognosis; Anemia;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study
Okamoto, Teppei
Noro, Daisuke
Hatakeyama, Shingo
Narita, Shintaro
Mitsuzuka, Koji
Sakurai, Toshihiko
Kawamura, Sadafumi
Hoshi, Senji
Shimoda, Jiro
Tanaka, Toshikazu
Kawaguchi, Toshiaki
Ishidoya, Shigeto
Ito, Akihiro
Tsuchiya, Norihiko
Habuchi, Tomonori
Ohyama, Chikara
BMC CANCER, 2021, 21 (01)
[2] COMPARISON OF UPFRONT ARAT THERAPY AND CAB THERAPY FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: A RETROSPECTIVE MULTICENTER STUDY
Shiraishi, Yusuke
Tobe, Taisuke
Ueki, Hideto
Suzuki, Kotaro
Hara, Takuto
Terakawa, Tomoaki
Teishima, Jun
Nakano, Yuzo
Miyake, Hideaki
Fujisawa, Masato
JOURNAL OF UROLOGY, 2024, 211 (05): : E1003 - E1004
[3] Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study
Yanagisawa, Takafumi
Fukuokaya, Wataru
Hatakeyama, Shingo
Narita, Shintaro
Muramoto, Katsuki
Katsumi, Kouta
Takahashi, Hidetsugu
Urabe, Fumihiko
Mori, Keiichiro
Tashiro, Kojiro
Iwatani, Kosuke
Shimomura, Tatsuya
Habuchi, Tomonori
Kimura, Takahiro
PROSTATE, 2025, 85 (02): : 165 - 174
[4] Indirect comparison of abiraterone acetate and docetaxel for treatment of metastatic "hormone-sensitive" prostate cancer
Feyerabend, S.
Saad, F.
Li, T.
Ito, T.
Diels, J.
Van Sanden, S.
De Porre, P.
Roiz, J.
Abogunrin, S.
Fizazi, K.
ANNALS OF ONCOLOGY, 2017, 28
[5] Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study
Kai Ozaki
Shingo Hatakeyama
Shintaro Narita
Kenichi Hata
Takafumi Yanagisawa
Toshikazu Tanaka
Kyo Togashi
Tomoko Hamaya
Teppei Okamoto
Hayato Yamamoto
Takahiro Yoneyama
Yasuhiro Hashimoto
Takahiro Kimura
Tomonori Habuchi
Chikara Ohyama
World Journal of Urology, 2023, 41 : 67 - 75
[6] Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study
Ozaki, Kai
Hatakeyama, Shingo
Narita, Shintaro
Hata, Kenichi
Yanagisawa, Takafumi
Tanaka, Toshikazu
Togashi, Kyo
Hamaya, Tomoko
Okamoto, Teppei
Yamamoto, Hayato
Yoneyama, Takahiro
Hashimoto, Yasuhiro
Kimura, Takahiro
Habuchi, Tomonori
Ohyama, Chikara
WORLD JOURNAL OF UROLOGY, 2023, 41 (01) : 67 - 75
[7] TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis
Pisano, Chiara
Turco, Fabio
Arnaudo, Elena
Fea, Elena
Vanella, Paola
Ruatta, Fiorella
Filippi, Roberto
Brusa, Federica
Prati, Veronica
Vana, Federica
Mennitto, Alessia
Cattrini, Carlo
Vignani, Francesca
Dionisio, Rossana
Icardi, Massimiliano
Guglielmini, Pamela
Buosi, Roberta
Stevani, Ilaria
Vormola, Roberto
Numico, Gianmauro
Depetris, Ilaria
Comandone, Alessandro
Gennari, Alessandra
Rossi, Maura
Airoldi, Mario
Vellani, Giorgio
Ortega, Cinzia
Tucci, Marcello
Di Maio, Massimo
Buttigliero, Consuelo
CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 56 - 67.e16
[8] Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer
Sathianathen, Niranjan J.
Oestreich, Makinna C.
Brown, Sarah Jane
Gupta, Shilpa
Konety, Badrinath R.
Dahm, Philipp
Kunath, Frank
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (12):
[9] Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients
Takashi Ueda
Kazutoshi Fujita
Mitsuhisa Nishimoto
Takumi Shiraishi
Masatsugu Miyashita
Naruhiro Kayukawa
Yuichi Nakamura
Satoshi Sako
Ryota Ogura
Atsuko Fujihara
Takafumi Minami
Fumiya Hongo
Koji Okihara
Kazuhiro Yoshimura
Hirotsugu Uemura
Osamu Ukimura
World Journal of Urology, 2022, 40 : 2939 - 2946
[10] Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients
Ueda, Takashi
Fujita, Kazutoshi
Nishimoto, Mitsuhisa
Shiraishi, Takumi
Miyashita, Masatsugu
Kayukawa, Naruhiro
Nakamura, Yuichi
Sako, Satoshi
Ogura, Ryota
Fujihara, Atsuko
Minami, Takafumi
Hongo, Fumiya
Okihara, Koji
Yoshimura, Kazuhiro
Uemura, Hirotsugu
Ukimura, Osamu
WORLD JOURNAL OF UROLOGY, 2022, 40 (12) : 2939 - 2946

← 1 2 3 4 5 →